bioAffinity Technologies, Inc. announced on May 7, 2025, the closing of its public offering, generating aggregate gross proceeds of $3.25 million. The offering consisted of 10,156,250 shares of common stock, or pre-funded warrants, combined with warrants to purchase up to 15,234,375 shares of common stock.
The combined public offering price for each share of common stock (or pre-funded warrant) and accompanying warrant was $0.32. WallachBeth Capital, LLC acted as the sole placement agent for the offering.
This capital raise provides essential funding for bioAffinity Technologies, supporting its ongoing operations and the commercialization efforts for its CyPath® Lung diagnostic test. The proceeds will be used for general corporate purposes, enabling the company to continue its strategic initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.